Key facts
- This page summarizes David Hung's Form 4 filing for NovoCure Ltd (NVCR).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 06 Jun 2024, 17:55.
David Hung - 05 Jun 2024 Form 4 Insider Report for NovoCure Ltd (NVCR)
- Reporting relationship
- Director
- Issuer ticker
- NVCR
- Reported as of
- 05 Jun 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 06 Jun 2024, 17:55:35 UTC
- Prior SEC filing
- 04 Mar 2024
- Next SEC filing
- 04 Mar 2025
- Source filing
- View source filing
- Reporting owner signature
- Ovie Onobrakpeya, as attorney in fact for Hung, David
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
David Hung filed Form 4 for NovoCure Ltd (NVCR) on 06 Jun 2024.
Change
- Previous filing in this sequence was filed on 04 Mar 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NVCR
transaction
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +4,053
- Change %
- +44%
- Price
- $0.000000
- Shares after
- 13,194
- Date
- 05 Jun 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
NVCR
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +6,229
- Change %
- Price
- $0.000000
- Shares after
- 6,229
- Date
- 05 Jun 2024
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 6,229
- Exercise price
- $23.13
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
These restricted stock units are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2025 annual general meeting of shareholders.
Footnote F2
Options to buy 6,229 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2025 annual general meeting of shareholders.